Lineage Cell Therapeutics
Income Statement

Last updated:

Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Lineage Cell Therapeutics's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 39% to $8,945,000. The net income raised on -$21,486,000 and profit margin reached -240%. Total operating expenses were $33,007,000.

Profit Margin

Lineage Cell Therapeutics, Inc. (AMEX:LCTX): Profit margin
2014 1.94M -36.41M -1870.75%
2015 2.53M -46.99M -1854.42%
2016 2.25M 33.57M 1490.76%
2017 1.79M -19.97M -1114.73%
2018 1.41M -45.99M -3247.88%
2019 1.47M -11.82M -800.2%
2020 773K -20.68M -2675.94%
2021 3.89M -38.56M -989.84%
2022 14.70M -26.35M -179.24%
2023 8.94M -21.48M -240.2%

LCTX Income Statement (2014 – 2023)

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue
Revenue
8.94M14.70M3.89M773K1.47M1.41M1.79M2.25M2.53M1.94M
Cost of revenue
671K728K1.42M385K412K302K168K358K1.10M837.05K
Gross profit
8.27M13.97M2.47M388K1.06M1.11M1.62M1.89M1.42M1.10M
Operating exp.
Research and development
15.70M13.98M33.91M12.31M17.94M20.95M24.02M36.10M42.60M37.53M
Selling and marketing
0000000000
Total operating expenses
33.00M36.49M51.68M26.83M39.94M42.10M42.28M60.86M67.23M51.79M
Operating income
-24.73M-22.52M-49.21M-26.44M-38.87M-41.79M-38.90M-58.96M-65.80M-50.68M
Other income (expenses), net
1.45M-3.29M5.94M4.52M19.64M-6.84M15.61M78.33M3.15M-472.13K
Income before tax
-23.28M-25.81M-43.27M-21.92M-19.23M-47.13M-23.28M18.62M-62.65M-51.15M
Income tax expense
-1.80M541K-4.70M-1.23M-7.40M-346K-37.29M-175.94M-4.51M-7.37M
Net income
-21.48M-26.35M-38.56M-20.68M-11.82M-45.99M-19.97M33.57M-46.99M-36.41M
Earnings per share
Basic EPS
-0.12-0.16-0.23-0.14-0.08-0.36-0.170.35-0.59-0.55
Diluted EPS
-0.12-0.16-0.23-0.14-0.08-0.36-0.170.34-0.59-0.55
Data sourceData sourceData sourceData sourceData sourceData sourceData sourceData sourceData sourceData source